Notification report

Full notification file

General information

Notification Number

Member State to which the notification was sent

Date of acknowledgement from the Member State Competent Authority

Title of the Project
Phase I study evaluating genetically modified autologous T cells expressing a T-cell receptor recognizing a cancer/germline antigen in patients with recurrent and/or refractory solid tumors ACTengine® IMA203-101)

Proposed period of release:
01/01/2020 to 31/01/2024

Name of the Institute(s) or Company(ies)
Immatics Biotechnologies GmbH, Paul-Ehrlich-Str. 15
72076 T├╝bingen

3. Is the same GMO release planned elsewhere in the Community?

Has the same GMO been notified elsewhere by the same notifier?

GMO characterization

GMO is a:
Other: mammals

Identity of the GMO:
The GMO is used as an investigational medicinal product (IMP) and consists of autologous patient-derived target-specific somatic CD3+ T cells expressing a TCR, which recognizes a specific cancer/germline antigen presented by HLA-A*02:01. The T cells have been transduced ex vivo with a third-generation self-inactivating (SIN) lentiviral vector that encodes for the specific T-cell receptor

Information relating to the recipient or parental organisms from wich the GMO is derived
Common NameGenusSpeciesSubspeciesStrainPathovar

European Commission administrative information

Consent given by the Member State Competent Authority:
10/03/2020 00:00:00